Supplementary Information

Phosphorylcholine antibodies restrict infarct size and left ventricular remodeling by attenuating the unreperfused post-ischemic inflammatory response in hypercholesterolemic APOE*3-Leiden mice

Niek J. Pluijmert¹, Rob C. M. de Jong²,³, Margreet R. de Vries²,³, Knut Pettersson⁴, Douwe E. Atsma¹, J. Wouter Jukema¹,³, Paul H. A. Quax²,³

¹ Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
² Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
³ Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
⁴ Athera Biotechnologies, Stockholm, Sweden
Supplementary Figures

**Supplemental Figure 1:** Circulating serum PC-mAb concentrations determined by ELISA 2 days and 3 weeks after MI. PC-mAb levels were only detectable in the PC-mAb treated group.

**Supplemental Figure 2:** PC-mAb affecting expression levels of CCL2. Cultured PBMCs isolated from human blood were treated with oxLDL in the presence or absence of PC-mAb with IgG isotype as a control. PC-mAb treatment resulted in a clear suppression of CCL2 levels.